A new vision for tackling key illnesses
June 11, 2019 | Cardiovascular disease (CVD) , Long Term Plan, diabetes
Steve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long-term Plan’s strategy for delivering more preventative, joined-up services for major health conditions
Introduction
The Long-term Plan furthers the NHS Five Year Forward View’s focus on cancer, mental health, diabetes, multimorbidity and healthy ageing. It also looks at other areas, such as cardiovascular and respiratory conditions, and explains how the NHS plans to change its approach in order to drive improvements in patient care and outcomes.
Cardiovascular disease (CVD)
Cardiovascular disease (CVD) has been identified in the Long-term Plan as “the single biggest area where the NHS can save lives over the next 10 years”. Detecting patients at risk of CVD and preventing the disease from occurring will be key to helping the NHS achieve its ambition.
In line with this, pharmacists and nurses in Primary Care Networks (PCNs) will be supported in identifying and treating relevant cohorts of patients. There will be a big focus on lifestyle improvements for at-risk patients, particularly weight management, as well as social prescribing. A new national CVD prevention audit will feed into the above activities.
There will also be a major structural change in stroke services, where hyper acute specialist stroke centres with new clot busting technology will be replacing existing stroke-receiving units.
Diabetes
The NHS plans to double the size of the NHS Diabetes Prevention Programme for type 2 diabetes. As with other disease areas, there will be a big emphasis on engaging patients in managing their health and also on disease prevention. Aligned with this weight management services will be critical, particularly in light of recent studies which have shown that if patients lose weight rapidly and significantly, it is possible to go into remission for type 2 diabetes.
The Long-term Plan shows how technology will help to move diabetes services out of hospitals and support self-care. For example, newly diagnosed patients will be offered expanding provision of structured education and digital self-management support tools including HeLP Diabetes – an online self-management tool for those with type 2 diabetes.
Cancer
The NHS aims to increase the number of cancer diagnoses at stage one and two from 50 percent of patients now to 75 percent by 2028. Changes will include modernising the Bowel Cancer Screening Programme and making the Faecal Immunochemical Test for haemoglobin easier for patients to use. The NHS will also implement HPV primary screening for cervical cancer across England by 2020.
The NHS plans to introduce a new faster diagnosis standard from 2020 to ensure that most patients receive a definitive diagnosis or ruling out of cancer within 28 days of referral from a GP or from screening.
The new diagnosis standard will be underpinned by a radical overhaul of the way diagnostic services are delivered for patients with suspected cancer. Starting this year, new Rapid Diagnostic Centres (RDCs) will be rolled out across the country to upgrade and bring together the latest diagnostic equipment and expertise. Cancer Alliances will also work with Integrated Care Systems (ICSs) to aid swift access to a consultant’s opinion.
Respiratory conditions
The NHS will build on the existing NHS RightCare programme to reduce variation across the country in the quality of spirometry testing, which is a key test for lung function. PCNs will support the diagnosis of respiratory conditions; while more staff in primary care will be trained and accredited to interpret test results.
Pulmonary rehabilitation, which involves activities such as breathing exercises and learning how to cope in an emergency, is one of the most expensive elements of the respiratory pathway. It will be run by multi-disciplinary teams using digital tools, such as My COPD, which is a toolkit for Clinical Commissioning Groups (CCGs).
Pharmacists will play a big role in managing respiratory care in PCNs. This will include medication reviews, educating patients and also advising on the use of inhalers – a critical task given that 90 percent of people use their inhaler incorrectly, according to the NHS.
Mental health
In the Long-term Plan, the NHS makes a new commitment to funding mental health services for children and young people, and pledges that this area will grow faster than both overall NHS funding and total mental health spending.
There is also a realisation that children’s mental health goes beyond the NHS; hence we expect to see multidisciplinary teams working in schools as the first point of contact for pupils.
The NHS promises to continue to expand access to IAPT services for adults and older adults with common mental health problems, with a focus on those with long-term conditions.
Digital services, such as mobile apps, are expected to play a big part in delivery and access to mental healthcare services, especially for children and young people.
Conclusion
While the detail varies in each health condition, there are many common themes, particularly with regards to illness prevention and the associated need to risk stratify patients; engage them in their treatment and encourage them to make lifestyle changes, where appropriate.
There is also a desire to deliver many services for these conditions in the community via integrated teams in PCNs. Consequently, it will be essential for pharma to think about how its products can deliver benefits across the whole care system and to determine how it can support the NHS in delivering more holistic, preventative care services.
Ends
Steve How and Oli Hudson are part of Wilmington Healthcare’s Consulting Team. For information on Wilmington Healthcare, visit www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Wilmington Healthcare appoints new Head of Digital
Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.In his new role,...
How has the pandemic reshaped the NHS in 2020?
Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset
How can pharma align its brand strategy with the NHS Reset?
Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era
Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs
White paper helps industry navigate new NHS roadmap
New report shows how pharma can support the NHS in the Covid-19 recovery era
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home
Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it